Centrosome duplication is critical for cell division, and genome instability can result if duplication is not restricted to a single round per cell cycle. Centrosome duplication is controlled in part by CP110, a centriolar protein that positively regulates centriole duplication while restricting centriole elongation and ciliogenesis. Maintenance of normal CP110 levels is essential, as excessive CP110 drives centrosome over-duplication and suppresses ciliogenesis, whereas its depletion inhibits centriole amplification and leads to highly elongated centrioles and aberrant assembly of cilia in growing cells 1, 2 . CP110 levels are tightly controlled, partly through ubiquitination by the ubiquitin ligase complex SCF cyclin F during G2 and M phases of the cell cycle 3 . Here, using human cells, we report a new mechanism for the regulation of centrosome duplication that requires USP33, a deubiquitinating enzyme that is able to regulate CP110 levels. USP33 interacts with CP110 and localizes to centrioles primarily in S and G2/M phases, the periods during which centrioles duplicate and elongate. USP33 potently and specifically deubiquitinates CP110, but not other cyclin-F substrates. USP33 activity antagonizes SCF cyclin F -mediated ubiquitination and promotes the generation of supernumerary centriolar foci, whereas ablation of USP33 destabilizes CP110 and thereby inhibits centrosome amplification and mitotic defects. To our knowledge, we have identified the first centriolar deubiquitinating enzyme whose expression regulates centrosome homeostasis by countering cyclin-F-mediated destruction of a key substrate. Our results point towards potential therapeutic strategies for inhibiting tumorigenesis associated with centrosome amplification.
Centrosome duplication is critical for cell division, and genome instability can result if duplication is not restricted to a single round per cell cycle. Centrosome duplication is controlled in part by CP110, a centriolar protein that positively regulates centriole duplication while restricting centriole elongation and ciliogenesis. Maintenance of normal CP110 levels is essential, as excessive CP110 drives centrosome over-duplication and suppresses ciliogenesis, whereas its depletion inhibits centriole amplification and leads to highly elongated centrioles and aberrant assembly of cilia in growing cells 1, 2 . CP110 levels are tightly controlled, partly through ubiquitination by the ubiquitin ligase complex SCF cyclin F during G2 and M phases of the cell cycle 3 . Here, using human cells, we report a new mechanism for the regulation of centrosome duplication that requires USP33, a deubiquitinating enzyme that is able to regulate CP110 levels. USP33 interacts with CP110 and localizes to centrioles primarily in S and G2/M phases, the periods during which centrioles duplicate and elongate. USP33 potently and specifically deubiquitinates CP110, but not other cyclin-F substrates. USP33 activity antagonizes SCF cyclin F -mediated ubiquitination and promotes the generation of supernumerary centriolar foci, whereas ablation of USP33 destabilizes CP110 and thereby inhibits centrosome amplification and mitotic defects. To our knowledge, we have identified the first centriolar deubiquitinating enzyme whose expression regulates centrosome homeostasis by countering cyclin-F-mediated destruction of a key substrate. Our results point towards potential therapeutic strategies for inhibiting tumorigenesis associated with centrosome amplification.
We recently characterized a novel human CP110-interacting protein, NEURL4, a daughter-centriole-specific protein that inhibits the formation of ectopic microtubule-organizing centres 4 . During the course of these studies, NEURL4 was independently found to interact with USP20 (also known as VDU2) in a proteome-wide screen for deubiquitinating enzyme (DUB)-associated proteins 5 . USP20 is highly related to a second DUB, USP33 (also known as VDU1), with which it shares ,59% amino acid identity, explaining their overlapping functions 6, 7 . Thus, we sought to examine whether USP20 and USP33 interact with the CP110-NEURL4 complex to regulate centrosome function. We immunoprecipitated each protein from human 293T-cell lysates, and found that endogenous USP33 and USP20 specifically interact with CP110 and NEURL4, but not with two other CP110-interacting proteins, CEP97 and cyclin F (Fig. 1a) . Moreover, these interactions were also observed in cells ectopically expressing Flagtagged CP110 (Flag-CP110) or Flag-USP33 (Fig. 1b and Supplementary Fig. 1a-e) . The interactions with USP20 and USP33 are probably direct because (1) bacterially expressed glutathione S-transferase (GST)-USP33 and USP20 bind to in vitro translated CP110 in binding assays ( Supplementary Fig. 1f ), and (2) NEURL4 depletion does not affect the binding between USP33 and CP110 ( Supplementary Fig. 1g ).
We found that endogenous USP33 and CP110 co-fractionate in at least three distinct protein complexes ranging from 0.4-1.3 megadaltons (MDa). This suggests the existence of larger CP110-USP33 deubiquitinase complexes that include proteins other than NEURL4 (Supplementary Fig. 2 ). Both USP33 and USP20 share three functional domains, a zinc-finger ubiquitin-binding motif (ZnF-UBP), a catalytic domain, and two domains present in ubiquitin-specific proteases (DUSP). We investigated the interaction between USP33 and CP110, and found that CP110 binds to a region of USP33 within its catalytic domain (Fig. 1b) .
USP33 and USP20 have been shown to partition to the cytoplasm, including the endoplasmic reticulum 8 , and a short isoform of USP33 localizes to the Golgi apparatus 9 . Because CP110 is a centrosomal protein, we visualized endogenous USP33, USP20, CP110 and other centrosomal markers in human osteosarcoma (U2OS) cells by indirect immunofluorescence. We observed USP33 localization to the cytoplasm, as expected, and we also found that USP33 co-localized with centrin 2 and c-tubulin, which are centrosomal markers (Fig. 2a, b and Supplementary Fig. 3a, b) . Notably, USP33 partially co-localized with CP110 at centrioles. USP33 localization appeared to be more proximal than CP110, suggesting that the former protein interacts with a subpopulation of CP110. A similar localization pattern was observed for a, HEK293T cell extracts were immunoprecipitated (IP) with the indicated antibodies (top), and western blots were probed as shown (right). Non-specific rabbit IgG was used as control. a-Tubulin is shown as a negative control. USP20 (data not shown). The centrosomal localization of USP33 is specific because it disappeared after USP33 was silenced with short interfering RNAs (siRNAs) (Supplementary Fig. 3c ). Because CP110 levels are high during S phase and low during G2/M owing to cyclin-Fmediated ubiquitination, we sought to determine the levels of USP33 in synchronized U2OS cells. USP33 associated with centrosomes predominantly in S and G2 phases of the cell cycle but less prominently in G1 phase, mirroring the abundance of CP110 protein during the cell cycle ( Fig. 2c and Supplementary Fig. 3d ) 1, 3 . Notably, USP33 protein levels also oscillated in parallel during cell-cycle progression, showing increased expression in S and early G2 phases and lower levels in late G2 and M phases (Figs 2d and 3b and Supplementary Fig. 3e ). We found that centrosomal targeting of USP33 is partially dependent on CP110, because depletion of CP110 reduced USP33 localization to centrosomes (see later) ( Supplementary Fig. 3f ).
DUBs are able to remove ubiquitin from proteins and regulate substrate abundance or function 5 . As USP33 and USP20 interact with CP110 at centrosomes, and CP110 protein levels correlated with USP33 and USP20 during the cell cycle, we investigated whether USP33 or USP20 might stabilize CP110. Interestingly, depletion of USP33 with siRNAs reduced CP110 levels by ,50%, whereas depletion of USP20 had a very modest impact on CP110 levels (Fig. 3a) , and co-depletion of USP20 with USP33 did not accentuate the impact of USP33 silencing. These results indicate that USP33 may have a more prominent role than USP20 in regulating CP110 stability; thus, we focused on the functional role of USP33. Importantly, cells treated with two different siRNAs targeting USP33 showed reduced levels of CP110, but not other CP110-interacting proteins, including NEURL4 and cyclin F (Supplementary Fig. 4a ). Moreover, USP33 depletion led to decreased CP110 intensity at centrioles in both U2OS and human telomerase reverse transcriptase (hTERT)-immortalized retinal pigment epithelial cells ( Supplementary Fig. 4b, c) . USP33 also stabilized CP110 in cells enriched in S and G2 phases ( Fig. 3b and Supplementary Fig. 4e, f) . Furthermore, USP33 suppression significantly reduced CP110 protein half-life from ,4.5 h to ,2 h ( Supplementary Fig. 4g , h). Because CP110 is a substrate of the SCF cyclin F ubiquitin ligase complex 3 , we examined the impact of USP33 on another SCF cyclin F substrate, RRM2 (ref. 10). We observed that USP33 depletion did not lead to a reduction in RRM2 levels ( Supplementary Fig. 4e , f), indicating that USP33 specifically stabilizes CP110.
Next, we examined whether stabilization of CP110 by USP33 is mediated through deubiquitination, because USP33 acts as a DUB. Remarkably, USP33 overexpression diminished CP110 ubiquitination provoked by ectopic production of cyclin F in cells (Fig. 3c ). CP110 deubiquitination was markedly attenuated when a catalytically inactive USP33 mutant (USP33 DM), in which cysteine 163 in the active site was replaced with a serine (C163S) and histidine 683 was modified to glutamine (H642Q), was transfected 11 . In addition, overexpression of two unrelated DUBs, USP1 and USP37, did not promote CP110 deubiquitination ( Fig. 3c and data not shown). To test whether deubiquitination by USP33 requires CP110 binding, first we mapped the region of CP110 that binds USP33 and found that the binding domain was located within the first 200 amino-terminal residues ( Supplementary  Fig. 1d) . Notably, when we tested a truncation mutant unable to bind USP33 (CP110 DN), we found that USP33 was unable to deubiquitinate this substrate (Fig. 3d) . In addition, we tested the activity of USP33 in an in vitro deubiquitination assay. We purified Flag-tagged USP33 and CP110, and the SCF cyclin F complex, from insect cells infected with baculoviruses 10 ( Supplementary Fig. 5a , b). CP110 was ubiquitinated in vitro by the SCF cyclin F complex specifically via a K48 ubiquitin linkage (data not shown). Ubiquitinated CP110 was deubiquitinated by wild-type USP33 protein, but not by a catalytically inactive mutant (USP33 DM) (Fig. 3e, f) . Moreover, USP33 activity was inhibited by ubiquitin aldehyde, a DUB inhibitor. Thus, USP33 specifically deubiquitinates CP110 in vitro and in vivo, explaining how USP33 stabilizes CP110.
To study the biological importance of USP33-mediated stabilization of CP110, we investigated whether USP33 depletion affects centrosome duplication. It has been shown that cyclin-F ablation leads to CP110 upregulation, which markedly induces centrosome amplification 3 . Indeed, cyclin-F knockdown induced centrosome amplification, visualized by the acquisition of more than four centrin 2 or CP110 foci and more than two c-tubulin foci, whereas co-depletion of USP33 with cyclin F reversed this phenotype in U2OS cells ( Fig. 4a and Supplementary Fig. 6a ). This phenotype was also observed in another cell line (HeLa) and was similarly reversed by treatment with distinct USP33 siRNAs ( Supplementary Fig. 6b ). The centrosome phenotype provoked by USP33 silencing was not due to altered cell-cycle progression ( Supplementary Fig. 6c ). Furthermore, we investigated whether USP33 depletion could affect centrosome re-duplication in cells treated with hydroxyurea (HU) to induce prolonged S phase. Similar to CP110 ablation 2 , depletion of USP33 significantly inhibited HU-induced centrosome amplification in two cell lines (Fig. 4b and Supplementary Fig. 6d ). Thus, although USP33 depletion did not affect normal centriole duplication (Fig. 4a) , silencing of USP33 specifically inhibited centrosome over-duplication, reminiscent of the CP110-depletion phenotype. Importantly, USP33 co-depletion rescued the mitotic defects observed in cyclin-F-depleted cells: whereas amplified centrosomes resulting from cyclin-F depletion led to multipolar and clustered bipolar (pseudo-bipolar) asymmetric spindles, co-silencing of USP33 and cyclin F reverted the frequency of mitotic aberrations to control levels ( Supplementary Fig. 6e ). These results suggest that destabilization of CP110 through USP33 silencing can inhibit mitotic errors wrought by centrosomal defects.
To investigate further the role of USP33 in regulating centrosome duplication, we ectopically expressed USP33 in U2OS cells synchronized by double-thymidine block and release. We found that
Figure 2 | USP33 localizes to centrosomes primarily during S and G2/M phases of the cell cycle. a, b, Co-localization of USP33 with CP110 and other centrosome and centriolar markers was visualized by immunofluorescence, as indicated. c, USP33 (red) and centrin 2 (green) were visualized throughout the cell cycle, as in panels a, b. DNA was stained with 49,6-diamidino-2-phenylindole (DAPI; blue). U2OS cells were treated with mimosine for G1-phase cells or were subject to double-thymidine block and release to enrich for S-and G2-phase cells. Cells with two centrin-2 dots were counted as G1-phase cells; those with three to four clustered centrin-2 dots as S-phase cells; and those with three to four centrin-2 dots, in which two pairs of dots were at least 3 mm apart, were counted as G2-phase cells. Localization of USP33 to centrosomes was most prominent in S and G2/M phases. d, USP33 protein levels parallel those of CP110 during the cell cycle. Cells were synchronized by double-thymidine block and release and synchronization confirmed by fluorescence-activated cell sorting (FACS) analysis (see Supplementary Fig. 3e ). AS, asynchronous; p-HH3, phospho-Ser-10-histone H3. Scale bars in a, c: 10 mm; b: 2 mm.
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expression of green fluorescent protein (GFP)-tagged wild-type USP33 significantly increased the percentage of cells with amplified centrin 2, CP110 and c-tubulin foci in comparison with the GFP control and USP33 DM mutant, and correlative light-electron microscopy confirmed the presence of bona fide ectopic centrioles and electron-dense structures, likely to be centriolar precursors or intermediates, in a subset of cells expressing GFP-USP33 ( Fig. 4c and Supplementary Fig. 7a-f) . Interestingly, we observed that the USP33 DM mutant also increased the percentage of cells with amplified centrioles. This may be due to residual activity of the mutant in vivo, additional, non-catalytic roles of USP33, or a combination of both. Alternatively, excessive amounts of USP33 DM might bind CP110, blocking it from accessing SCF cyclin F
. USP33 promotes the generation of excessive centriolar foci due to increased levels of CP110 because (1) overexpression of human or murine USP33 led to CP110 upregulation in multiple cell lines ( Supplementary Fig. 7c, d) , and (2) depletion of CP110 overrode USP33-mediated generation of centriolar foci ( Supplementary Fig. 7g-i) . In sum, increased levels of USP33 positively regulate centrosome duplication by augmenting CP110 levels, and loss of USP33 can prevent centrosome amplification and mitotic defects.
Centrosome amplification is frequently detected in human cancers, and it has been implicated as a contributing factor during cellular transformation 12, 13 . Interestingly, a search of an integrated cancer microarray database (Oncomine) revealed that USP33 gene expression is significantly upregulated in pancreatic cancer 14, 15 ( Supplementary  Fig. 9a ). This was of particular interest because centrosome amplification can be detected in primary pancreatic ductal carcinomas (PDAC) 16, 17 , and because a mouse model suggested that supernumerary centrosomes can promote chromosomal aberrations and pancreatic cancer progression 18 . Therefore, we examined USP33 and CP110 levels in human pancreatic cell lines and tissue samples. Remarkably, USP33 and CP110 were both substantially upregulated in cultured PDAC cell lines as compared to normal pancreatic epithelial cells, and USP33 and CP110 levels were strongly correlated (Supplementary Fig. 8a) . Furthermore, depletion of USP33 in two PDAC cell lines (Panc1 and MiaPaCa2) led to a reduction in CP110 levels (Supplementary Figs 4d and 6d), indicating that USP33 stabilizes CP110 in PDAC cells. Notably, CP110 and USP33 levels also correlated with centrosome amplification in pancreatic cells ( Supplementary Fig. 8a, b) , and we found that USP33 and CP110 depletion inhibited prolonged S-phase centrosome amplification in MiaPaCa2 cells (Supplementary Fig. 6d) .
Next, we examined USP33 and CP110 protein levels using human tissue arrays that included PDAC and histologically normal pancreatic samples. Two separate arrays were scored using a four-tier grading system. Notably, we found that both USP33 and CP110 were highly expressed in PDAC but not in normal pancreas, and the levels of USP33 and CP110 were significantly correlated in the same tissue samples (Supplementary Fig. 9b ). In addition, we also visualized CP110, acetylated tubulin, c-tubulin and keratin 19, a marker of pancreatic ducts and PDAC cells, using a tissue microarray containing 30 additional, independent cases of PDAC. In histologically normal ducts, a normal pattern of centriolar CP110 staining and ciliary acetylated tubulin staining was most frequently encountered (Supplementary Fig. 9c ). In contrast, CP110 overexpression was observed in PDAC cells in 29 of 30 cases. Our results suggest that the abundance of centrosome regulators, such as USP33 and CP110, may be mis-regulated in human tumours that are associated with centrosomal defects, although additional studies will be needed to elucidate the temporal connections between de-regulated expression of these proteins, centrosome aberrations, and PDAC pathogenesis.
We have identified USP33 as a centrosomal DUB that stabilizes CP110 at centrioles through deubiquitination. USP33 positively by nickel-NTA chelation chromatography, and western blots were probed with antibodies against CP110. An unrelated DUB (USP1) expressed as a control had no effect on CP110 ubiquitination. WCE, whole-cell extract. IB, immunoblot. d, Deubiquitination by USP33 requires selective binding to an amino-terminal portion of CP110. 293T cells were transfected with indicated GFP-and Flag-tagged (F) plasmids and processed as in c. Asterisks indicate non-specific bands. e, f, In vitro deubiquitination reactions were performed using wild-type ubiquitin (Ub) (e) or a mutant form of ubiquitin (Ub-K0) in which all lysines have been mutated (f), and analysed by western blotting with the indicated antibodies. g, The ubiquitin mutant (Ub-K0) lacks the ability to form poly-ubiquitin chains and can only be conjugated to substrate as monoubiquitin. In vitro deubiquitination of CP110 was blocked by simultaneous incubation with ubiquitin aldehyde (Ub-H) as indicated.
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regulates centrosome duplication by regulating CP110 abundance. Together with the finding that SCF cyclin F promotes the ubiquitination and degradation of CP110 (ref.
3), we have uncovered an underlying cycle in which the equilibrium between ubiquitination and deubiquitination governs the levels of a critical centrosome protein during the cell cycle, thereby ensuring centrosome homeostasis. Disruption of either the deubiquitinating or ubiquitinating enzymes could upset this equilibrium and lead to centrosome aberrations. Ubiquitinating and deubiquitinating enzymes have been the subject of intense scrutiny in cancer research, and inhibitors of the enzymes that promote or remove ubiquitin, including USP33, are targets for drug development 12, 19, 20 . As many human tumours are associated with centrosome amplification and genomic instability, our findings suggest the possibility of therapeutic intervention in cancers with this hallmark.
METHODS SUMMARY
Plasmids. Human and murine USP33 complementary DNAs were provided by G. Wu 6,7 and S. Shenoy
11
. USP33 mutants were generated by the QuikChange Sitedirected Mutagenesis kit (Stratagene). CP110 and cyclin-F constructs have been described 3 . Biochemical methods. Extract preparation, immunoprecipitation and immunoblotting have been described [1] [2] [3] [4] . Immunofluorescence microscopy. Indirect immunofluorescence procedures have been described [1] [2] [3] . Briefly, cells were fixed with cold methanol for 2 min or with 10% formalin solution (Sigma-Aldrich) for 8 min, followed by permeabilization with PBS and 1% Triton X-100 for 5 min and blocking in PBS, 0.1% Triton X-100 and 3% BSA for 1 h, before incubation with primary antibodies for 2 h. Cy3-conjugated donkey anti-rabbit IgG (Jackson Immunolabs) or Alexa-Fluor-488-conjugated donkey anti-mouse IgG (Invitrogen) were used as secondary antibodies. DNA was stained with DAPI. Prolong Gold (Invitrogen) was used to mount slides. Images were acquired with a Zeiss Axiovert 200 M microscope (363  objective lens, N.A. 1.4, 1.63 Optovar), equipped with a cooled Retiga 2000R CCD (QImaging). Some images represent the maximum projection of 12 deconvoluted planes using Metamorph (Molecular Devices).
Full Methods and any associated references are available in the online version of the paper. 
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METHODS
Cell culture and cell-cycle synchronization. HeLa, U2OS, RPE1-hTERT, HEK-293T, COS-1 and COS-7 were obtained from ATCC and maintained according to their instruction. Pancreatic cell lines were provided by J. Pollack. Early passages of cells were used, and they were not constitutively cultured for more than 2 months. For cell-cycle synchronization, HeLa or U2OS cells were cultured in the presence of 2 mM thymidine (Sigma) for 16 h, washed twice with medium, and released into fresh medium without thymidine for 8 h. After another 16 h block in thymidine, cells were washed twice, released to fresh medium, and collected at indicated time points (5 h, S phase; 10 h, G2 phase). Nocodazole (100 ng ml
21
) was added 5 h after release from the thymidine block to block cells in pro-metaphase. Transient transfections. siRNAs were transfected into HeLa, U2OS or RPE-1 cells using siIMPORTER (Millipore), HiPerFect (Qiagen) or Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Plasmids were transfected into HeLa and U2OS cells using FuGene6 (Roche) or Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. HEK-293T, COS-1 and COS-7 cells were transfected using the calcium phosphate method, as described [1] [2] [3] . Antibodies. Rabbit polyclonal antibodies against CP110 (ref. . The siRNA sequence for USP20 was GGACAAUGA UGCUCACCUAUU 11 . The siRNA sequence for NEURL4 was CCAUCAUG CAAGACGGUAAUU 4 . In vivo deubiquitination assay. The methods to detect ubiquitinated protein were modified from ref. 21. HEK293 cells were transiently transfected with pcB6-His ubiquitin (gift from R. Baer), HA-or Flag-tagged CP110, cherry-cyclin F, GFP, GFP-USP33 wild type, GFP-USP33 catalytic mutant, or GFP-USP1 (a gift from T. Huang), as indicated. After 36 h, cells were treated with 10 mm MG132 (Peptides International) for 4 h, cells were lysed and briefly sonicated in Buffer A (100 mM NaH 2 PO 4 , 10 mM Tris-Cl, 6 M guanidine-HCl, 10 mM imidazole pH 8.0). The cell lysates were incubated with nickel-NTA resin (Qiagen) to precipitate His-tagged ubiquitinated proteins for 3 h at room temperature (24 uC). Ni-NTA beads were subjected to two washes with buffer A, two washes with buffer A/TI (1 volume buffer A and 1 volume TI buffer) (TI buffer, 25 mM Tris-Cl pH 6.8 and 20 mM imidazole), and then one wash with TI buffer. Finally, Ni-NTA beads were eluted in SDS loading buffer containing 200 mM imidazole, separated by SDS-PAGE, and detected by immunoblotting. In vitro deubiquitination assay. Flag-tagged USP33 and CP110 and the SCF cyclin F complex (comprising GST-SKP1, His-tagged CUL1, ROC1 and His-tagged cyclin F) were individually affinity purified using anti-Flag (CP110 and USP33) or glutathione-agarose (SCF cyclin F ) chromatography from extracts of baculovirus-infected insect cells 10 . CP110 was ubiquitinated in vitro by purified SCF cyclinF complex in ubiquitination reaction buffer (50 mM Tris-HCl pH 7.6, 5 mM MgCl 2 , 1 mM okadaic acid and 0.6 mM dithiothreitol (DTT)) containing 2 mM ATP, 0.1 mM E1 (Boston Biochem),10 ng ml 21 Ubch3, 10 mg ml 21 Ubch5c and 2.5 mg ml 21 ubiquitin wild type or ubiquitin-k0 (Boston Biochem). Ubiquitinated CP110 was then diluted tenfold with deubiquitination reaction buffer (20 mM HEPES pH 7.6, 50 mM NaCl, 1 mM EDTA, 0.2 mg ml 21 BSA, 1 mM DTT, 100 mM MG132, 1 mM AEBSF, 2 mg ml 21 aprotinin). Diluted ubiquitinated CP110 was incubated with 10 ng ml 21 USP33 protein at 30 uC for the indicated time (0-1.5 h). For the reactions with ubiquitin aldehyde, 8 mM ubiquitin aldehyde (Boston Biochem) was added. Samples were separated by SDS-PAGE, and detected by immunoblotting.
Correlative light-electron microscopy. U2OS cells were plated at low confluence on gridded glass bottom dishes (MatTek) and transfected with GFP-USP33/RFPcentrin 2 or GFP along/RFP-centrin 2 using FuGene 6. After 48 h, cells were examined by live-cell imaging to monitor green and red fluorescence and to obtain phase contrast images. Cells with both GFP and RFP expression were documented, and their relative positions on the grids were recorded. Cells were then fixed with 0.1 M sodium cacodylate buffer (pH 7.4) supplemented with 2.5% glutaraldehyde, and 1 mM CaCl 2 , and then processed in a standard manner for transmission electron microscopy, as previously described 4 . Tissue microarray. Pancreatic tissue arrays were purchased from US Biomax (PA1001 and PA207). Immunohistochemical staining was performed as described 22 and scored by two independent pathologists using a four-tier grading system (0 5 negative, 1 5 weak, 2 5 moderate and 3 5 strong staining intensity). Immunofluorescent staining was performed as described 23 . Statistical analyses. All data represent the average from at least three independent experiments with at least 100 cells counted per experiment unless otherwise indicated. Significance was calculated by two-tailed Student's t-test or analysis of variance ( Supplementary Fig. 6e ) using GraphPad software. Differences were considered significant when P , 0.05. 
